AIRES (Artificial Intelligence for Reconstruction of Echocardiography)
Research type
Research Study
Full title
Echocardiographic detection of cardiac function using the Ventripoint (VMS+) and Ligence Heart AI echocardiography systems versus conventional echocardiography analyses and cardiac MRI in patients receiving chemotherapy: a pilot study
IRAS ID
349258
Contact name
Sandeep S Hothi
Contact email
Sponsor organisation
THE ROYAL WOLVERHAMPTON NHS TRUST
Duration of Study in the UK
2 years, 0 months, 30 days
Research summary
Breast cancer is the second most prevalent cancer worldwide, causing 11.6% of global cancer diagnoses. Chemotherapy with trastuzumab is an important part of treatment but carries a potential risk of chemotherapy-induced cardiotoxicity, observed as clinical or subclinical left ventricular dysfunction. The implications of such cardiotoxicity are important, to both the chemotherapy regime as well as to cardiac function.
Cardiotoxicity is currently routinely assessed through 2D and where possible 3D echocardiography imaging techniques. These techniques are prone to inter-operator variability, poor image quality and require significant expert time to conduct and report. Where image quality is poor additional testing such as cardiac MRI and contrast echo is required.
This study aims to assess two novel systems (V-echo and L-echo) involving both additional spatial monitoring data input and artificial intelligence driven processing and reporting to overcome the afore mentioned issues with current echo imaging.
Outcomes from this study will include accuracy, workflow impact, cost analyses and acceptability to both patients and staff of the V-echo and L-echo systems.REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
25/NW/0273
Date of REC Opinion
25 Sep 2025
REC opinion
Favourable Opinion